| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8466414 | Cytokine & Growth Factor Reviews | 2016 | 28 Pages |
Abstract
Delineating how IFN-β exerts its action on different T cell types may eventually contribute to the designing of therapeutic strategies aiming to improve the effectiveness of this drug for MS treatment.
Keywords
PD-LTregPRRPLPSOCSMMP9NMOPAMPIRFEAEUSP18APCNaBTFHCXCRTr1C-X-C chemokine receptorPDCMBPGITRLVLA4TFRMIPMOGCCRPBMCTNFFOXP3ubiquitin specific peptidase 18Very late antigen 4C-C chemokine receptorIFNARProteolipid proteinSTATNeutralizing antibodyantigen-presenting cellexperimental autoimmune encephalomyelitisinflammationpathogen-associated molecular patterninterferonInterferon betaIFNinterleukinforkhead box P3CNST cell subsetsBBBsuppressor of cytokine signalingPeripheral blood mononuclear cellPlasmacytoid dendritic cellT regulatory cellT helper cellT follicular helper cellNeuromyelitis opticacentral nervous systeminterferon regulatory factortumor necrosis factorFoxaBlood-brain barrierCSFCerebrospinal fluidSignal transducer and activator of transcriptionMetalloproteinase-9Multiple sclerosismacrophage inflammatory proteinMyelin basic proteinlymph nodesmyelin oligodendrocyte glycoproteininterferon receptorpathogen recognition receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Nadia Kavrochorianou, Melina Markogiannaki, Sylva Haralambous,